Shanti Pandey, Kavita Pandey, Vijay Joshi, Swati Gupta, Kalpana

Department of Ophthalmology, GMC Haldwani, Nainital, Uttarakhand, India

E-mail of Corresponding Author: vijay_joshi01@yahoo.com

ABSTRACT

Retinoblastoma is a primary malignant neoplasm of the retina that arises from immature retinal cells which affects infants and children and it is the most common primary tumor of the eye in children. Retinoblastoma detected on time can lead the child to see and moreover can save his life. Retinoblastoma in later stages can endanger life. It becomes essential to know most about this life threatening as well as sight threatening condition. Let these children live and enjoy the color of life.

Keywords: Retinoblastoma, chemotherapy, tumor, eye

INTRODUCTION

Retinoblastoma is a primary malignant neoplasm of the retina that arises from immature retinal cells which affects infants and children and it is the most common primary tumor of the eye in children.1

Out of newly diagnosed cases of retinoblastoma only 6% are familial while 94% are sporadic. Bilateral retinoblastoma are germline in all cases. Only 15% of unilateral retinoblastoma are caused by germline mutation, remaining 85% are sporadic.2 In 1971, Knudson proposed twohit hypothesis suggesting that in hereditary cases, germline mutations are present in all cells and somatic mutation occur only in retinal cells so they predisposed to nonocular carcinomas whereas in unilateral sporadic cases both hits occur during development of retina so no risk of secondary malignancy.3

In 1800s enucleation was the primary therapy to save life of the child. Then in early 1900s, external beam radiotherapy salvaged the life of child at the cost of poor vision and phthisis bulbi, secondary malignancy and orbital bone growth retardation. Refinements in radiotherapy including plaque beam therapy, laser therapy, thermotherapy, cryotherapy and latest being periocular carboplatin injections has been done.

In 1996, Kingston et al4 showed that ocular salvage rate improved to 90% if chemoreduction therapy is given prior to radiotherapy for intraocular retinoblastoma.

In a study on 158 eyes treated with vincristine, etoposide and carboplatin regimen given in six cycles, all retinoblastoma, vitreous seeds and subretinal seeds initially regressed but at least one vitreous seed recurrence was seen in 50% cases and at least one subretinal seed recurrence in 62% cases at 5 years follow up.5

Recent concept is of synergistic therapy (chemothermotherapy or chemocryotherapy) applying chemoreduction and focal tumor consolidation consecutively on tumor and seeds. Shields et al6 showed the recurrence in 18% cases treated with chemoreduction and thermotherapy compared with recurrences in 45% cases treated with chemotherapy alone in 7 year follow up in 457 patients of retinoblastoma. Studies showed similar effect on macular retinoblastoma.7

Various studies on high risk retinoblastomas showed that high dose chemotherapy in
conjunction with autologous stem cell rescue have highly improved the prognosis in these cases.\textsuperscript{8}

Various presentation of retinoblastoma

![Diffuse Infiltrative Retinoblastoma With Placoid Thickening And Retinoblastoma With Intraorbital Extension](image)

Figure 1: Diffuse Infiltrative Retinoblastoma With Placoid Thickening And Retinoblastoma With Intraorbital Extension

![Retinoblastoma Presenting As Orbital Cellulitis](image)

Figure 2: Retinoblastoma Presenting As Orbital Cellulitis

**Diagnosis of retinoblastoma**

A thorough clinical evaluation with indirect ophthalmoscopy and ultrasonography B-scan, can establish the diagnosis of retinoblastoma.\textsuperscript{14} USG B-scan shows typical intra-lesional calcification of retinoblastoma. Computed tomography and magnetic resonance imaging are indicated when extraocular or intracranial spread of tumor is suspected.\textsuperscript{14} Retcam is a wide angle fundus camera
which helps in documenting retinoblastoma and monitoring of tumor regression on follow up.

**Classification of retinoblastoma**

The Reese Ellworth classification was introduced to prognosticate patients treated with methods other than enucleation mainly external beam radiotherapy.  

**Group I**
- a) solitary tumor, < 4 disc diameters in size, at or behind the equator
- b) multiple tumor, none > 4 disc diameters in size, at or behind the equator

**Group II**
- a.) solitary tumor, 4–10 disc diameters in size, at or behind the equator
- b) multiple tumor, 4–10 disc diameters in size, behind the equator

**Group III**
- a) any lesion anterior to the equator
- b) solitary tumor >10 disc diameters behind the equator

**Group IV**
- a) multiple tumors, some >10 disk diameters
- b) any lesion extending anteriorly to the oraserrata

**Group V**
- a) massive tumor involving more than half of retina
- b) vitreous seedings

**International retinoblastoma staging system** is based on collective information gathered by the clinical evaluation, imaging, systemic survey and histopathology.

**Stage 0:** No enucleation (one or both eyes may have intraocular disease)

**Stage I:** Eye enucleated, completely resected histologically

**Stage II:** Eye enucleated with microscopic residual tumor

**Stage III:** Regional extension
- a) Overt orbital disease
- b) Preauricular or cervical lymph node extension

**Stage IV:** Metastatic disease
- a) Hematogenous metastasis
  1. single lesion
  2. multiple lesions
- b) CNS extension:
  1. Prechiasmatic lesion
  2. CNS mass
  3. Leptomeningeal disease

**Management of retinoblastoma**

The management of retinoblastoma is a multidisciplinary approach, depends on the stage of the disease and it is highly individualized. There are several methods to manage intraocular retinoblastoma namely - focal methods like cryotherapy, laser photocoagulation, transpupillary thermotherapy and plaque brachytherapy; local methods like enucleation and external beam radiotherapy and systemic therapy like chemotherapy

**Chemotherapy**

Chemotherapy is currently the primary therapeutic option in most children with bilateral retinoblastoma and in some children with unilateral disease when the affected eye is believed to be salvageable. Chemoreduction refers to a process involving reduction in tumor volume after chemotherapy. It is not effective alone but in adjunct with focal therapy it can avoid enucleation or external beam radiotherapy without significant toxicity. The most common chemotherapeutic regimen in use around the world today consists of a combination of carboplatin, etoposide or a related drug, and vincristine (CEV regimen) for 6 cycles. In some centers, cyclosporine is added to this regimen to reduce the multidrug resistance that occurs in many retinoblastomas. Several promising new drugs and alternative regimens are currently being evaluated. Thiotepa used in the treatment of ovarian and breast cancer, penetrates well into the brain, and has been considered for HDC. The investigators observed considerable, but manageable, toxicity with high-dose thiotepa. A response of retinoblastoma to conventional dose thiotepa is documented in one case. For all these reasons, Kremens et al decided to include
thiotepa into the HDC regimen for children with high-risk RB. Thus High Dose Chemotherapy with thiotepa, etoposide and carboplatin may represent a curative option for children with extrabulbar or disseminated retinoblastoma. Standard chemotherapy is given in 6 cycles; after first 2 cycles, local therapy in form of cryotherapy, thermotherapy or plaque radiation may be given to completely regressed tumors. Chemoreduction therapy is most successful for tumors without intravitreal and subretinal seedings. Risk factors for recurrence of tumor, subretinal seed and vitreous seed recurrence include:

a. Tumor with subretinal seeding at initial presentation

b. Younger patients with large bulky tumor.

In cases of recurrence, external beam radiotherapy and/or enucleation is required. A study revealed that non-caucasian race, male sex and Rees Ellsworth group V had higher rate of tumor recurrence.

Adverse effects of chemotherapy include myelosupression, febrile episodes, neurotoxicities and non specific gastrointestinal toxicities. Matsubara et al. used high-dose chemotherapy (HDC) with autologous stem cell transplantation (SCT) in patients with metastatic retinoblastoma without CNS involvement. Melphalan was a key drug, and was administered in combination with other agents such as cisplatin, cyclophosphamide, carboplatin or thiotepa. Similarly Dunkel IJ et al. suggested an intensive multimodality therapy for patients with stage 4a metastatic retinoblastoma. They concluded that intensive multimodality therapy including high-dose chemotherapy (carboplatin and thiotepa alone or with etoposide or topotecan) with autologous hematopoietic stem cell rescue was curative for the majority of patients with stage 4a metastatic retinoblastoma. The contribution of external beam radiation therapy is unclear. They also suggested similar therapy for stage 4B retinoblastoma (central nervous system metastatic disease) and concluded that intensive multimodality therapy may be beneficial for such patients but longer follow-up is required to determine whether it has been curative.

They also described a series of 13 patients with trilateral retinoblastoma treated with similar intensive chemotherapy, and concluded that intensive chemotherapy is potentially curative for some patients with trilateral retinoblastoma, especially those with localized (M-0) disease.

**Periocular Chemotherapy**

Periocular (subtenon) carboplatin injections are currently being evaluated as an adjunct to intravenous chemotherapy in management of Rees Ellsworth Group VB retinoblastoma with vitreous seeds. Honavar et al. did study which showed that periocular chemotherapy can achieve 70% eye salvage in patients with retinoblastoma with diffuse vitreous seeds.
Figure 3: Chemotherapy for retinoblastoma. (A) Pretreatment appearance of macular retinoblastoma. (B) Same lesion after two cycles of chemotherapy using vincristine, etoposide, and carboplatin.

Enucleation

Enucleation still remains important therapeutic option for unilateral advanced intraocular retinoblastoma and some cases of bilateral far-advanced disease not amenable to any eye-preserving therapy. Primary enucleation remains treatment of choice for advanced intraocular retinoblastoma with neovascularisation of iris, secondary glaucoma, anterior chamber tumor invasion, tumors occupying >75% of vitreous volume, necrotic tumors with secondary orbital inflammation and tumors with hyphema or vitreous hemorrhage where tumor characteristics cannot be recognized especially when only one eye is involved.  

There are specific considerations while enucleating an eye with retinoblastoma.

| a. | Minimal manipulation while surgery $^{25}$ |
| b. | Avoid perforation of eye |
| c. | Harvest long optic nerve stump (>15mm) and never <10mm $^{25}$ |
| d. | Inspect enucleated eye for macroscopic extraocular extension or optic nerve involvement. |
| e. | Harvest fresh tissues for genetic studies |
| f. | Avoid biointegrated implant if postoperative radiation therapy is necessary. |
During enucleation, a 10-15mm long section of the optic nerve should be removed as the principal route of exit of tumor cells from the eye is along the optic nerve for which traction sutures applied over recti muscles and a 15 degree blunt tipped and angled tenotomy scissors or even straight scissors may be used. Pathological studies have shown enucleation to be curative if >5mm of optic nerve is sacrificed. 

Necrotic tumor with aseptic orbital cellulitis and phthisis bulbi should be imaged before enucleation to rule out extraocular extension. Enucleation should be done when inflammation has subsided with brief course of preoperative oral and topical steroids. Phthisis bulbi usually follows spontaneous tumor necrosis and an episode of aseptic orbital cellulitis. Enucleation in these cases is often complicated by intraoperative bleeding and excessive periorbital fibrosis. Insertion of an orbital implant at the time of enucleation appears to be appropriate except when there is a strong likelihood of residual tumor in the orbit which may require orbital radiation therapy. Biointegrated implants are avoided if adjunctive postoperative radiotherapy is necessary because implant vascularity is compromised by radiotherapy which increases risk of implant exposure. Myoconjunctival technique and custom ocular prosthesis have optimized prosthetismotility and static cosmesis.

**External Beam Radiation Therapy**

Nowadays external beam radiation therapy is indicated when focal therapy or chemotherapy fails to control tumor or very rarely when chemotherapy is contraindicated. It is also applicable to eyes containing one or more tumors that involve the optic disc and eyes that show diffuse intravitreal or subretinal seeding. Standard target doses of radiation to the eye and orbit are in the range of 40–50 Gy given in multiple fractions of 150–200 cGy over 4–5 weeks.

External beam radiation therapy results in two main patterns of regression. In the first pattern (type I), the tumor regresses to an almost exclusively calcific, avascular residual mound. In the second pattern (type II), the tumor regresses without prominent calcification but with a gray-tan fish-flesh appearance. The dilated retinal vessels usually become markedly attenuated with both regression patterns. In type III regression, a combination of both regression patterns occurs. Major complications of external beam radiation therapy are stunting of orbital growth leading to cosmetic facial deformity, dry eye, radiation cataract, radiation retinopathy and optic neuropathy.

Cataract typically begins as posterior subcapsular clouding and usually does not form for at least 6 months after radiation therapy and is often delayed for as much as 1–1.5 years after treatment. External beam radiation therapy also increases the risk of nonretinoblastoma malignancies in the field of treatment in survivors of germinal retinoblastoma by 30% compared to less than 6% chance in those who do not receive external beam radiotherapy. This effect also appears most pronounced in children irradiated before the age of 1 year.

**Plaque Radiation Therapy**

In some children who have relatively large but localized retinoblastomas (less than 16mm in basal diameter and less than 8 mm in thickness), that does not involve optic disc or maculae in the presence of limited localized vitreous seeding, plaque radiation therapy may be employed successfully. Plaque radiation therapy entails surgical implantation of a radioactive device (eye plaque containing radioisotope iodine-125 and ruthenium-106) of appropriate size and strength on the sclera overlying the intraocular tumor, leaving the plaque in place for a sufficient period of time (usually 2–5 days) to provide a predetermined radiation dose to the apex of the tumor, and subsequent surgical removal of the plaque. Currently it is performed as primary management only when chemotherapy is contraindicated. It is most useful as secondary management in tumors...
which fail to respond to either chemotherapy or external beam radiotherapy or in cases of tumor recurrences.

The advantages of plaque radiation therapy are focal delivery of radiation with minimal damage to surrounding normal structures, minimal periorbital tissue damage, absence of cosmetic deformity.

Figure 4: Plaque radiation therapy for retinoblastoma. (A) Pretreatment appearance of macular retinoblastoma. (B) Regressed lesion 6 weeks following iodine-125 notched plaque radiotherapy

**Laser photocoagulation**

In photocoagulation, an argon green laser is employed using an indirect ophthalmoscope delivery system to delimit the tumor and coagulate the blood supply with two rows of overlapping laser burns. Laser photocoagulation is useful for small tumor 4mm in basal diameter and 2mm in thickness. Complications are transient serous retinal detachment, retinal vascular occlusion, retinal hole, retinal traction and preretinal fibrosis.
Now with the advent of thermotherapy laser photocoagulation is less commonly used. Infact it is contraindicated when patient is on active chemoreduction protocol.14

**Thermotherapy**

In transpupillary thermotherapy (TTT),34 an infrared laser beam (wavelength 810 nm) is directed at the retinal tumor using an operating microscope or indirect ophthalmoscope delivery system to induce tissue necrosis,35 by achieving a temperature of 40-60 degree celsius within the tumor with sparing of retinal vessels until it appears homogeneously dull white. Large spot sizes (generally 2–3mm in diameter) are used if the pupil can be dilated widely. Infrared radiation can also be given by transscleral route with a diopexy probe.

Thermotherapy is most appropriate for small intraretinal (4mm in basal diameter and 2mm in thickness) extramacular and extrapapillary tumors in eyes with clear optic media.35 It is not applicable to tumor associated with intravitreal or subretinal tumor seeds or retinal detachment. Common complications of thermotherapy are focal iris atrophy, focal paraxial lens opacity, retinal traction and serous retinal detachment.

Major application of thermotherapy is as an adjunct to chemotherapy. The heat amplifies cytotoxic effects of platinum analogues. This synergistic combination with chemoreduction therapy is known as chemothermotherapy.

**Cryotherapy**

Trans-scleral cryotherapy is an obliterative focal treatment method that destroys targeted intraocular tissues by means of freezing36 using an insulated retinal cryoprobe and indirect ophthalmoscopy. Double freeze-thaw method or triple freeze-thaw method may be applied according to the size of the tumor.

This treatment is most applicable to small to medium size retinal tumors with minimal or no intravitreal or subretinal seeds or associated retinal detachment when the tumors are located in the equatorial or pre-equatorial region of the fundus.36 Complications include serous retinal detachment, rhegmatogenous retinal detachment and retinal tear. Cryotherapy administered 2-3 hrs. before chemotherapy increase the delivery of chemodrugs across the blood retinal barrier and thus have synergistic effects.14

**High risk retinoblastoma**

High risk factors predictive of systemic metastasis include anterior chamber seedings, iris infiltration, ciliary body infiltration, massive choroidal infiltration, retrolaminar optic nerve invasion, invasion of optic nerve up to transaction, scleral infiltration and extrascleral extension.37

Current protocol is to administer standard dose chemotherapy including carboplatin, vincristine and etoposide in six cycles following enucleation in high risk characteristic patients. Those cases with invasion of optic nerve transaction, sclera infiltration or extrascleral extension are treated with 12 cycles of HDC, orbital external beam radiotherapy, and/or enucleation8

**Orbital retinoblastoma**

Orbital retinoblastoma refers to orbital extension of retinoblastoma in the form of sclera infiltration, extrascleral extension or optic nerve invasion. When orbital extension is present at the time of diagnosis of tumor, it refers to primary orbital retinoblastoma. Orbital recurrence after uneventful enucleation for intraocular retinoblastoma is referred to as secondary retinoblastoma. Sometimes inadvertent perforation, fine needle aspiration biopsy or intraocular surgery is done in cases of unsuspected retinoblastoma, orbital extension and systemic dissemination occurs. This orbital extension is called as accidental orbital retinoblastoma. Previously unrecognized orbital extension discovered macroscopically or microscopically at time of enucleation is referred as overt or microscopic overt retinoblastoma.38

Technetium -99 bone scan and PET-computed tomography can help in early detection of these subclinical metastasis.
Honavar et al developed a multimodality treatment protocol for management of orbital retinoblastoma which begins with 3 cycles of high dose chemotherapy followed by enucleation or orbital exentration, orbital external beam radiotherapy and finally extended 12 cycles of standard dose chemotherapy. Early results of this treatment protocol are encouraging. Some cases of retinoblastoma require intraocular surgery like cataract surgery for radiation cataract, sclera buckling or pars planavitrectomy for retinal detachment or vitreous hemorrhage. Specific guidelines for intraocular surgery after treatment of retinoblastoma have been described.

**Metastatic retinoblastoma**

Metastasis in retinoblastoma, which commonly spreads to orbital and regional lymph nodes, CNS, bones and bone marrow, usually develops within first year of diagnosis and the chances are very less after 5 years of diagnosis. Until recently the prognosis of metastatic disease was very poor. Various studies using high dose chemotherapy with autologous stem cell transplantation produced promising results in the cure of metastatic retinoblastoma especially those in bone and bone marrow. Still CNS metastasis have grave prognosis and longer follow up is required to confirm the results of these studies.

**Genetic counseling**

It is an important aspect in management of retinoblastoma. In patients with positive family history, 40% of the siblings would be at risk of developing retinoblastoma and 40% of the offsprings may develop retinoblastoma. In unilateral non familial retinoblastoma, 1% of siblings and 8% of offsprings would be affected. In cases of bilateral nonfamilial retinoblastoma, 6% of siblings and 40% of offsprings are at risk of developing retinoblastoma. Various studies on mutational analysis of RB1 gene have shown that by identifying specific mutations, screening tests can be designed which help in computing specific antenatal risks.

**CONCLUSION**

Retinoblastoma is a primary malignant neoplasm of the retina that arises from immature retinal cells which affects infants and children and it is the most common primary tumor of the eye in children. Retinoblastoma detected on time can lead the child to see and moreover can save his life. Retinoblastoma in later stages can endanger life.

It becomes essential to know most about this life threatening as well as sight threatening condition. Let these children live and enjoy the color of life.

**REFERENCES**


